Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Jonathan Berardi
Observed name:
Berardi, Jonathan
Institutions:
NewYork–Presbyterian Hospital,
Rutgers New Jersey Medical School,
Weill Cornell Medical Center
Observed institutions:
NewYork–Presbyterian Hospital,
Weill Cornell Medicine,
Rutgers New Jersey Medical School,
Weill Cornell Medical Center
ORCID:
0000-0003-3415-2056
Observed ORCID:
0000-0003-3415-2056
OpenAlex ID:
A5080598648
Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial
2021
·
Philippe Bégin
, Jeannie Callum
, et al.
·
Nature Medicine
·
277
PDF
Tecovirimat for the Treatment of Mpox
2026
·
Jason Zucker
, William A. Fischer
, et al.
·
New England Journal of Medicine
·
45
Tecovirimat Treatment of People With HIV During the 2022 Mpox Outbreak: A Retrospective Cohort Study
2023
·
Jacob McLean
, Kate Stoeckle
, et al.
·
Annals of Internal Medicine
·
44
PDF
Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19
2023
·
Teresa H. Evering
, Kara W. Chew
, et al.
·
Annals of Internal Medicine
·
35
PDF
Safety and efficacy of inhaled interferon-β1a (SNG001) in adults with mild-to-moderate COVID-19: a randomized, controlled, phase II trial
2023
·
Prasanna Jagannathan
, Kara W. Chew
, et al.
·
EClinicalMedicine
·
15
Post-acute COVID-19 outcomes including participant-reported long COVID: amubarvimab/romlusevimab versus placebo in the ACTIV-2 trial
2024
·
Teresa H. Evering
, Carlee Moser
, et al.
·
EClinicalMedicine
·
7
Association of long COVID with health-related quality-of-life outcomes
2026
·
Malini M. Gandhi
, Carlee Moser
, et al.
·
Scientific Reports
·
4
PDF
Author Correction: Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial
2022
·
Philippe Bégin
, Jeannie Callum
, et al.
·
Nature Medicine
·
4
PDF
The federated trials approach; an opportunity for global collaboration in health emergencies
2026
·
Inge Christoffer Olsen
, Lu Zheng
, et al.
·
EClinicalMedicine
·
3
214. Clinical Characteristics and Outcomes of Patients Treated with Tecovirimat for Mpox Disease: A Large Cohort in New York City
2025
·
Ciarra Leocadio
, Elizabeth A Garcia
, et al.
·
Open Forum Infectious Diseases
·
2
PDF
Tecovirimat treatment of clade II mpox: a virological analysis of a randomised, double-blind, phase 3 trial
2026
·
Dariia Vyshenska
, Jonathan C Reed
, et al.
·
The Lancet Microbe
·
1
Clinical Outcomes of Mpox Disease in Patients Treated With Tecovirimat
2025
·
Ciarra Leocadio
, Elizabeth A Garcia
, et al.
·
Clinical Infectious Diseases
·
1
Reply to: Concerns about estimating relative risk of death associated with convalescent plasma for COVID-19
2022
·
Philippe Bégin
, Jeannie Callum
, et al.
·
Nature Medicine
·
1
Association of long COVID with health-related quality-of-life outcomes
2026
·
Gelman, Michael
, Moyano, Susana
, et al.
·
Carolina Digital Repository (University of North Carolina at Chapel Hill)
PDF
P-218. Examining CD4, Viral Load and STI Co-Infection as Predictors of Severe Mpox Outcomes Among a Cohort of People with HIV in New York City
2026
·
Ofole Mgbako
, Alex J Pelliccione
, et al.
·
Open Forum Infectious Diseases
Show more works
View as search
Works count:
15
Citation count:
439
H-index:
6
I10-index:
5
Year
Topic
Type